Rexgenero receives Scientific Advice letter from the Paul Ehlich Institute (PEI)

08/10/2015

Rexgenero receives scientific advice from the Paul Ehlich Institute (the German pharmaceutical regulator) regarding quality and clinical aspects of Rexgenero planned phase III study with REX-001 in critical limb ischemia following a meeting with PEI on 8th September 2015. The PEI confirmed that the proposed multi-centre, randomized placebo-controlled design as well as the dose and primary endpoint is acceptable.

innovative cell therapies
Contact us